<DOC>
	<DOC>NCT00596297</DOC>
	<brief_summary>The purpose of this study is to determine whether preoperative intravitreal bevacizumab is effective in reducing intra-operative and postoperative bleeding in diabetic patients submitted to pars plana vitrectomy for vitreous hemorrhage.</brief_summary>
	<brief_title>Preoperative Bevacizumab for Vitreous Hemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Vitreous Hemorrhage</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temazepam</mesh_term>
	<criteria>Diabetic retinopathy causing significant vitreous hemorrhage with visual acuity loss lasting more than three months in patients not previously treated and four months in those previously LASER treated. Previous intraocular surgery other than cataract surgery Retinal detachment Use of anticoagulants drugs other than aspirin Vitreous hemorrhage clearance at week3 study period History of previous thromboembolic events</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Vitreous Hemorrhage</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>pars plana vitrectomy</keyword>
	<keyword>preoperative</keyword>
</DOC>